HRP20030894A2 - Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg - Google Patents

Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg Download PDF

Info

Publication number
HRP20030894A2
HRP20030894A2 HR20030894A HRP20030894A HRP20030894A2 HR P20030894 A2 HRP20030894 A2 HR P20030894A2 HR 20030894 A HR20030894 A HR 20030894A HR P20030894 A HRP20030894 A HR P20030894A HR P20030894 A2 HRP20030894 A2 HR P20030894A2
Authority
HR
Croatia
Prior art keywords
day
disorder
mammal
ocd
use according
Prior art date
Application number
HR20030894A
Other languages
English (en)
Croatian (hr)
Inventor
Stephen
Jonathan
Charles R Ashby Jr
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of HRP20030894A2 publication Critical patent/HRP20030894A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20030894A 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg HRP20030894A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
PCT/US2002/014344 WO2002092071A1 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Publications (1)

Publication Number Publication Date
HRP20030894A2 true HRP20030894A2 (en) 2004-06-30

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030894A HRP20030894A2 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Country Status (18)

Country Link
US (2) US6462084B1 (https=)
EP (1) EP1392273A4 (https=)
JP (1) JP2004533445A (https=)
KR (1) KR20040028758A (https=)
CN (1) CN1509168A (https=)
BR (1) BR0209614A (https=)
CA (1) CA2446641A1 (https=)
CZ (1) CZ20033379A3 (https=)
HR (1) HRP20030894A2 (https=)
HU (1) HUP0400032A3 (https=)
IL (1) IL158761A0 (https=)
MX (1) MXPA03010406A (https=)
NO (1) NO20035037L (https=)
NZ (1) NZ529613A (https=)
PL (1) PL367362A1 (https=)
TW (1) TWI313599B (https=)
WO (1) WO2002092071A1 (https=)
YU (1) YU89103A (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345602B1 (en) 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
WO2004002462A2 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
EP1617862B1 (en) * 2003-04-25 2012-12-05 Allergan, Inc. Botulinum neurotoxin for treating obsessive compulsive behavior symptoms
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0543780A3 (en) 1991-11-21 1993-09-01 Ciba-Geigy Ag Novel aminoalkanephosphinic acids and their salts
HU222776B1 (hu) * 1992-05-20 2003-10-28 Northwestern University (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
RU2214241C2 (ru) 1996-06-28 2003-10-20 Орто-Макнейл Фармасьютикал, Инк. Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
MXPA01004015A (es) * 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
DE60007078T2 (de) 1999-02-01 2004-12-16 Ortho-Mcneil Pharmaceutical, Inc. Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
WO2000061140A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing

Also Published As

Publication number Publication date
US20020169103A1 (en) 2002-11-14
TWI313599B (en) 2009-08-21
EP1392273A1 (en) 2004-03-03
NO20035037L (no) 2004-01-07
HUP0400032A3 (en) 2012-09-28
PL367362A1 (en) 2005-02-21
YU89103A (sh) 2006-08-17
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (en) 2002-11-21
NZ529613A (en) 2006-09-29
KR20040028758A (ko) 2004-04-03
HUP0400032A2 (hu) 2004-04-28
CA2446641A1 (en) 2002-11-21
CN1509168A (zh) 2004-06-30
EP1392273A4 (en) 2004-11-24
IL158761A0 (en) 2004-05-12
BR0209614A (pt) 2004-12-07
US6462084B1 (en) 2002-10-08
CZ20033379A3 (cs) 2004-12-15
JP2004533445A (ja) 2004-11-04
NO20035037D0 (no) 2003-11-13

Similar Documents

Publication Publication Date Title
Wright Pharmacologic effects of ketamine and its use in veterinary medicine
US5788986A (en) Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression using R enantiomers, S enantiomers, and racemic mixtures of selective serotonin reuptake inhibitor compounds or their active metabolites
HRP20030894A2 (en) Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
Essig Clinical and experimental aspects of barbiturate withdrawal convulsions
IE850099L (en) Analgesic compositions
SI21169A (sl) Nova uporaba peptidnega razreda spojine za zdravljenje alodinije ali drugih različnih vrst kronične ali fantomske bolečine
ES2220047T3 (es) Conbinacion de un antagonista selectivo de nmda nr2b y un inhibidor de la cox-2.
Kushida et al. Soft-diet feeding decreases dopamine release and impairs aversion learning in Alzheimer model rats
JP2021511365A (ja) ５−ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法
Russo et al. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity
HRP20020286A2 (en) Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog
Faingold et al. Drugs for the control of epilepsy
AU2002259153B2 (en) Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
AU2002259153A1 (en) Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
Avanzini et al. Epilepsy and Neurotransmitters Basis for a New Pharmacological Approach to Antiepileptic Therapy
US7737180B2 (en) Use of neboglamine (CR 2249) as an antipsychotic and neuroprotective
JP2008506630A (ja) ゾルピデムの更なる治療的使用
Zhang et al. Effects of 1, 1‐dimethylguanidine administration on blood pressure, heart rate and renal sympathetic nerve activity in normotensive and spontaneously hypertensive rats
Leme et al. EFFECT UPON THE ANALGESIC ACTION OF RESERPINE OF CENTRAL NERVOUS SYSTEM STIMULANTS AND DRUGS AFFECTING THE METABOLISM OF CATECHOL‐AND INDOLE‐AMINES
Barnes et al. Effect of Genetic Background on Ionotropic Glutamate Receptor and Neurotrophin Biology: Synaptic Connectivity and Function in Neurological Disease
Manasa Experimental Evaluation of Anticonvulsant Activity of Hydrocotyle Asiatica Linn (Centella Asiatica) in Albino Mice
Barnes et al. Effect Connectivity Receptor of Genetic and and Background Neurotrophin Function in on Neurological Biology: Ionotropic Synaptic Glutamate
Ravenscroft Molecular and behavioural pharmacology of parkinsonism and associated dyskinesias
Sherif et al. Acute vigabatrin-phenobarbitone-interaction on exploratory behaviour of rats
Erhardt Importance of endogenous kynurenic acid in brainm catecholaminergic processes and in the pathophysiology of schizophrenia

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused